Related Experiment Video
Updated: Aug 15, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Current understanding of coronary in-stent restenosis. Pathophysiology, clinical presentation, diagnostic work-up,
1Kardiologie, Klinikum der Ludwig-Maximilians-Universität München--Innenstadt, Ziemssenstrasse 1, 80336 München, Germany. Thomas.Schiele@med.uni-muenchen.de
Insights
In-stent restenosis, a complication of coronary stents, affects 250,000 patients annually. While difficult to manage, irradiation and drug-eluting stents show promise for treatment and prevention.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
Background:
- In-stent restenosis (ISR) is a major limitation after coronary stent implantation, causing significant morbidity and economic burden.
- Approximately 250,000 ISR lesions require management globally each year.
- ISR management is challenging, with high repeat restenosis rates regardless of angioplasty device.
Purpose of the Study:
- To review the pathophysiology, epidemiology, predictors, and diagnostic work-up of ISR.
- To emphasize current and emerging treatment options for ISR prevention and therapy.
Main Methods:
- Review of histological and molecular findings related to ISR pathophysiology.
- Analysis of epidemiological data and predictors of ISR.
- Evaluation of treatment strategies including irradiation and drug-eluting stents.
Main Results:
- ISR pathophysiology involves inflammation, smooth muscle cell migration/proliferation, and extracellular matrix formation.
- Adjunctive irradiation significantly reduces repeat ISR incidence by 50%.
- Early clinical trials of drug-eluting stents for ISR show promising results, suggesting they may become the preferred treatment.
Conclusions:
- ISR is a complex multifactorial process with significant clinical and economic impact.
- Irradiation and drug-eluting stents represent effective strategies for managing and preventing in-stent restenosis.
- Further research and clinical application of these advanced therapies are warranted.
Abstract:
In-stent restenosis is the limiting entity following coronary stent implantation. It is associated with significant morbidity and cost and thus represents a major clinical and economical problem. Worldwide, approximately 250 000 in-stent restenotic lesions per year have to be dealt with. The pathophysiology of instent restenosis is multifactorial and comprises inflammation, smooth muscle cell migration and proliferation and extracellular matrix formation, all mediated by distinct molecular pathways. Instent restenosis has been recognised as very difficult to manage, with a repeat restenosis rate of 50% regardless of the mechanical angioplasty device used. Much more favourable results were reported for the adjunctive irradiation of the in-stent restenotic lesion, with a consistent reduction of the incidence of repeat in-stent restenosis by 50%. Data from the first clinical trials on drug-eluting stents for the treatment of in-stent restenosis have shown very much promise yielding this strategy likely to become the treatment of choice. This review outlines the histological and molecular findings of the pathophysiology, the epidemiology, the predictors and the diagnostic work-up of in-stent restenosis and puts emphasis on the various treatment options for its prevention and therapy.
Related Concept Videos
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:26Atherosclerosis III: Management